{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bauer J"],"funding":["Deutsche Forschungsgemeinschaft","Wilhelm Sander-Stiftung","Deutsche Krebshilfe","José Carreras Leukämie-Stiftung","Else Kröner-Fresenius-Stiftung"],"pagination":["6401"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9613889"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma. DNAJB1-PRKACA-derived HLA class I and HLA class II ligands induce multifunctional cytotoxic CD8<sup>+</sup> and T-helper 1 CD4<sup>+</sup> T cells, and their cellular processing and presentation in DNAJB1-PRKACA expressing tumor cells is demonstrated by mass spectrometry-based immunopeptidome analysis. Single-cell RNA sequencing further identifies multiple T cell receptors from DNAJB1-PRKACA-specific T cells. Vaccination of a fibrola"],"journal":["Nature communications"],"pubmed_title":["The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma."],"pmcid":["PMC9613889"],"funding_grant_id":["EXC2180 390900677","DJCLS 05 R/2017","70114948","2016.177.3","2022_EKTP03"],"pubmed_authors":["Bilich T","Brecht IB","Maringer Y","Dicks S","Kohler N","Denk M","Richter M","Schroeder S","Hailfinger S","Bauer J","Holzer U","Bonzheim I","Feucht J","Bitzer M","Boerries M","Walz JS","Klein R","Wacker M","Bucher P","Salih HR","Scheid J","Rammensee HG","Luibrand J","Zwick M","Nelde A","Dubbelaar M","Ebinger M","Rieth J","Heitmann JS"],"additional_accession":[]},"is_claimable":false,"name":"The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.","description":"The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma. DNAJB1-PRKACA-derived HLA class I and HLA class II ligands induce multifunctional cytotoxic CD8<sup>+</sup> and T-helper 1 CD4<sup>+</sup> T cells, and their cellular processing and presentation in DNAJB1-PRKACA expressing tumor cells is demonstrated by mass spectrometry-based immunopeptidome analysis. Single-cell RNA sequencing further identifies multiple T cell receptors from DNAJB1-PRKACA-specific T cells. Vaccination of a fibrola","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-28T03:35:36.025Z","creation":"2024-11-12T07:53:12.493Z"},"accession":"S-EPMC9613889","cross_references":{"pubmed":["36302754"],"doi":["10.1038/s41467-022-33746-3"]}}